Vivo Bio Tech: Promoter entities exit via 18 lakh shares

Vivo Bio Tech Limited disclosed a set of off-market share transfers dated August 21, 2026, involving promoter-group entities, along with a separate acquisition disclosure from a non-promoter investor. The key change was that two promoter affiliates reduced their holdings to zero after transferring a combined 18,00,000 equity shares. One of these transfers also resulted in Dwight Technologies Private Limited increasing its stake through an off-market acquisition of 12,00,000 shares.

The disclosures were made to BSE under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The company also clarified that these off-market transfers did not alter its equity share capital or diluted share capital.

Maxcell Communication transfers 12,00,000 shares off-market

Maxcell Communication India Private Limited, identified as a promoter group entity, transferred 12,00,000 equity shares of Vivo Bio Tech Limited off-market on August 21, 2026. The transaction resulted in a complete exit of Maxcell Communication from the company, with its post-transfer holding disclosed as nil. Prior to the transfer, the promoter-group entity held 12,00,000 shares, which was reported as 5.41% of the company.

The intimation was signed by Gangireddy Suresh, Director at Maxcell Communication India Private Limited, and filed with BSE as required under SEBI SAST Regulation 29(2). The disclosure also stated that the company’s share capital structure remained unchanged due to the transaction.

Dwight Technologies acquires 12,00,000 shares, raises total holding

Dwight Technologies Private Limited disclosed that it acquired 12,00,000 equity shares of Vivo Bio Tech Limited (5.41%) through an off-market transaction on August 21, 2026. Following the purchase, Dwight Technologies’ total holding increased to 30,72,561 shares. This was reported as 13.85% of the company’s total voting capital and 10.48% of its diluted share capital.

The acquirer described itself as Hyderabad-based and confirmed in the filing that it does not belong to the promoter or promoter group of Vivo Bio Tech. Like the promoter-side disclosure, the transaction was reported under SEBI SAST Regulation 29(2).

P.K.L Solution transfers 6,00,000 shares, stake falls to nil

In a separate filing, Vivo Bio Tech disclosed that another promoter group entity, P.K.L Solution Private Limited, transferred 6,00,000 equity shares off-market on August 21, 2026. This reduced P.K.L Solution’s stake from 2.70% to nil. The intimation was signed by Jaivardhan Prasadam, Director of P.K.L Solution Private Limited (DIN: 00097958), and submitted to BSE under SEBI SAST Regulation 29(2).

The disclosure did not indicate any change in the company’s capital base due to the transfer. The identity of the counterparty for this 6,00,000-share transfer was not included in the provided details.

Share capital and diluted capital remain unchanged

Vivo Bio Tech reported that its total equity share capital remained at 2,21,90,628 equity shares of face value ₹10 each. This corresponds to a paid-up equity share capital of about ₹22.19 crore. The company also disclosed a total diluted share capital of 2,93,23,111 equity shares, factoring in 6,27,409 warrants and 63,22,000 ESOPs.

The filings stated that there were no changes to either total equity share capital or diluted share capital as a result of the off-market transfers described as inter-se transfers.

Key transaction snapshot

Corporate governance and other regulatory updates referenced

Apart from the SAST disclosures, Vivo Bio Tech also referred to compliance-related board approvals and filings. The board approved the Board Report, Corporate Governance Report, and Management Discussion and Analysis for the financial year ended March 31, 2026, along with annexures as required under regulatory standards. The company said these disclosures were made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and cited a SEBI Master Circular dated January 30, 2026.

Separately, the company noted it initiated a postal ballot process for shareholder approval for the re-appointment of Mr. Kalyan Ram Mangipudi as Whole-time Director. The postal ballot also covers two related party transactions, including an annual limit of ₹30 crore with Virinchi Limited, as disclosed.

FY26 financial performance disclosed earlier

Vivo Bio Tech reported a consolidated net loss of about ₹1.71 crore for FY26, compared with a consolidated net profit of about ₹7.28 crore in the previous year. At the same time, total income increased to about ₹53.78 crore for FY26, as stated in the provided data. The company also disclosed it published the audited financial results in newspapers on June 2, 2026, in compliance with Regulation 30 of SEBI LODR.

The filings cited here focus on shareholding and compliance disclosures and do not provide additional operating commentary beyond the stated financial outcome.

Other SAST disclosure: Vivo Bio Tech in Virinchi warrant conversion

The provided information also references a separate SAST Regulation 29(2) filing involving Vivo Bio Tech as an acquirer in Virinchi Limited. According to the details, Vivo Bio Tech disclosed conversion of 13,15,715 warrants into equity shares at an issue price of ₹28 per share (face value ₹10 and premium ₹18). The application money received was stated as ₹2.76 crore.

The filing described Vivo Bio Tech as a promoter group entity in the context of Virinchi Limited. It also stated that Vivo Bio Tech’s direct shareholding in Virinchi increased from 37,84,285 shares (3.48%) to 51,00,000 shares (4.69%), while total holdings including outstanding warrants were indicated as unchanged at 14.71%.

Market impact and what investors can take away

From a market-structure perspective, the August 21, 2026 disclosures indicate a clean reduction of promoter-group affiliate holdings to zero in two entities, alongside a disclosed non-promoter stake increase by Dwight Technologies. Because the transactions were off-market, the filings mainly help investors track shifts in ownership rather than provide price discovery signals. The company explicitly stated that its equity capital and diluted capital remained unchanged, which means the event is about transfer of existing shares rather than issuance or cancellation.

The repeated use of Regulation 29(2) filings also highlights how substantial changes in holdings are captured through SAST disclosures, enabling investors to reconcile changes in shareholding patterns with disclosed counterparties when available.

Conclusion

Vivo Bio Tech’s August 21, 2026 SAST disclosures show promoter-group entities Maxcell Communication India Private Limited and P.K.L Solution Private Limited exiting their holdings through off-market transfers of 12,00,000 and 6,00,000 shares, respectively. Dwight Technologies Private Limited disclosed it acquired the 12,00,000 shares and raised its total holding to 30,72,561 shares. The company’s equity share capital (2,21,90,628 shares) and diluted capital (2,93,23,111 shares) were stated to remain unchanged, with further updates expected through routine exchange filings tied to shareholder approvals and regulatory reporting.